[Blood transfusion, short perioperative intraportal chemotherapy and recurrence of colorectal cancer].
Carcinomatous tumors usually have a rather slow proliferation rate. However, this process is sensibly accelerated as soon as immunodepressive phenomena occur. Blood transfusions may result in the appearance of a considerable mass of alloantigens and in simultaneous immunomodulation. On the basis of a series of 469 patients, we are able to realize that the intra-and postoperative administration of blood during the curative resection of colorectal cancers produced a poor prognosis. We also followed up subjects who had had chemotherapy via the portal system for one week but no blood transfusion. The prognosis was definitely better in these patients, and proved to be 2 to 3 times as favorable as for patients receiving blood transfusions without chemotherapy. The various results are thoroughly analyzed, the primary aim being the study of the effects of intraoperative portal chemotherapy. This leads to advocating the restriction of blood transfusions, and the use of autotransfusion or hemodilution if required.
Harder
F
F
Laffer
U
U
Berres
M
M
Jäggi
P
P
Metzger
U
U
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001803:Blood Transfusion; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007432:Intraoperative Period; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D065227:Transfusion Reaction
Transfusion sanguine, chimiothérapie intraportale périopératoire de courte durée et récidive du cancer colorectal.